Xalkori (crizotinib capsules and oral pellets) — Cigna
Melanoma, Cutaneous (ALK fusion or ROS1 fusion)
Initial criteria
- Patient age ≥ 18 years
- Patient has anaplastic lymphoma kinase (ALK) fusion disease OR patient has ROS1 fusion disease
Approval duration
1 year